Neuro Pain Medical Center

12/16/2025

Helping Light the Way Forward for Alzheimer’s Psychosis

Do you or a loved one living with Alzheimer’s disease experience distressing hallucinations or delusions? These symptoms, known as Alzheimer’s Disease Psychosis (ADP), can include seeing things others don't, feeling like possessions are being stolen, or believing the person in the mirror is a stranger.

The Radiant Study is looking for volunteers to help evaluate a potential new study drug to see if it is safe and effective at reducing these symptoms.

🏥 Who Can Participate? You may be eligible to join if you:

* Are between 55 and 95 years old.

* Live at home, in a nursing home, or in an assisted-living facility.

* Have probable Alzheimer’s with symptoms of psychosis.

* Have a care partner who can attend study visits with you.

🧪 Study Details

Duration: Approximately 4 months.

Treatment: Participants will take one capsule daily (either the study drug or a placebo).

Visits: Includes one screening visit and about five study center visits with your care partner.

Next Steps: Participants may have the option to join an open-label extension study afterward.

📍 Local Study Site

Dr. Perminder Bhatia, M.D.
Neuropain Medical Center
736 E. Bullard Street (Suite 101),
Fresno, CA 93710

Interested in learning more? Participation is entirely voluntary. Contact our team today to ask questions and see if this study is the right fit for you and your family.

📞 Call us at: 559.437.9700

02/07/2025

Hope for children and teens with migraines! A research study is currently enrolling children and adolescents to investigate a new investigational drug for migraine treatment. This could be a chance to find better migraine management for your child.

Call our office for more details (559) 437-9700

To pre-qualify for this study, your child must:

• Be 12 to 17 years of age and have migraines
• Have 8 or more migraine attacks per month with 15 or more headache days
• Be currently taking or have taken in the past at least 1 oral medication (examples include ibuprofen, Tylenol®, aspirin, ExcedrinR, or a prescription medication) for the treatment of a migraine attack

12/17/2024

🌟 Join the Fight Against Alzheimer’s Disease! 🧠

Are you between 65 and 80 years old? Have you noticed changes in your memory or thinking, or are you concerned about your risk for Alzheimer’s disease?

💡 The TRAILRUNNER-ALZ 3 Study is seeking participants to help researchers test an investigational medicine aimed at treating early Alzheimer’s disease.

By participating, you can:
✔️ Contribute to groundbreaking research
✔️ Receive specialized care and check-ins
✔️ Access study-related medicines at no cost

🔍 Eligibility:
• Age 65–80
• Mild memory changes or concerns
• Willingness to complete a blood test
• A reliable study partner who can assist you

Make a Difference Today!
Join us in advancing medical research and improving the lives of people with Alzheimer’s disease.

📲 Click the link to learn more or see if you qualify: https://neuropain.com/research/ or call us at (559) 437-9700

11/01/2024

🌟 Do migraines affect your life? We can help! 🌟

Participate in Migraine Research - Join a clinical research study to help discover new treatments!

🧒 For Children: Ages 6–18 with Acute or Chronic Migraines
👩‍🦰 For Adults: Ages 18–80 with Acute, Episodic, Chronic, or Menstrual Migraines

Take part in cutting-edge research and help find new migraine treatments for you and others! Qualified participants may receive study-related care at no cost and may be compensated for their time and travel.

👉 Limited spots available! Learn more or see if you qualify today.

09/30/2024

🦶 Struggling with Neuropathy? We’re here to help! 🌟

Our latest clinical study is now enrolling participants. If you experience symptoms like tingling, numbness, or pain due to neuropathy, this is your opportunity to take part in cutting-edge research that could lead to new treatments.

💡 Qualified participants will receive:

* Expert medical care at no cost
* Possible compensation for your time
* A chance to make a real difference for those living with neuropathy

Don't miss your chance to contribute to future advancements in care. Click the link to see if you qualify!

09/18/2024

In July, the FDA approved Kisunla for people with mild cognitive impairment and dementia.

On Monday, one of the first patients in the United States received the drug intravenously at the office of Dr. Perminder Bhatia in northeast Fresno.

09/11/2017

Listen to Dr. Bhatia's interview on Central Valley Talk

Visit http://NeuroPain.com or call (559) 437-9700. You can also visit 736 E. Bullard Ave., Fresno, CA 93710

02/24/2017

We are actively recruiting patients for clinical research and trials at no cost to the patient. Our staff is well trained in “Good Clinical Practice“ aka GCP providing ethical and highest scientific quality in conducting, recording and reporting trial results. Visit our website to sign up for more information or to browse answer to your frquently asked questions about clinical trials.